Evidence map›Paper›PMID 33368171›Full record

ArticleJournal of the American Geriatrics Society2021

End-of-Life Cost Trajectories in Cancer Patients Treated by Medicare versus the Veterans Health Administration.

Risha Gidwani, Steven M Asch, Jack Needleman, Katherine Faricy-Anderson, Derek B Boothroyd, Samantha Illarmo, Karl A Lorenz, Manali I Patel, Gary Hsin, Kavitha Ramchandran and 1 more

Open access · greenAbstract read
In one paragraph

Article in Journal of the American Geriatrics Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 2 pooled it
0.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 syntheses or guidelines pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Risha GidwaniHealth Economics Resource Center, VA Palo Alto Health Care System, Palo Alto, California, USA.
Steven M AschCenter for Innovation to Implementation, VA Palo Alto Health Care System, Palo Alto, California, USA.
Jack NeedlemanDepartment of Health Policy and Management, UCLA Fielding School of Public Health, University of California, Los Angeles, California, USA.
Katherine Faricy-AndersonProvidence VA Medical Center, Providence, Rhode Island, USA.
Derek B BoothroydQuantitative Sciences Unit, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.
Samantha IllarmoHealth Economics Resource Center, VA Palo Alto Health Care System, Palo Alto, California, USA.
Karl A LorenzCenter for Innovation to Implementation, VA Palo Alto Health Care System, Palo Alto, California, USA.
Manali I PatelCenter for Health Policy/Center for Primary Care and Outcomes Research, Stanford University School of Medicine, Stanford, California, USA.
Gary HsinDivision of Primary Care and Population Health, Stanford University School of Medicine, Stanford, California, USA.
Kavitha RamchandranDivision of Oncology, Stanford University School of Medicine, Stanford, California, USA.
Todd H WagnerHealth Economics Resource Center, VA Palo Alto Health Care System, Palo Alto, California, USA.
VA Palo Alto Health Care System · USStanford University · USCenter for Innovation · USBrown University · USUCLA Health · US

Funding

Translational Oncology Research Program (Project-005)P30CA124435 · NCI · STANFORD UNIVERSITY · PI Vittorio Sebastiano · 2007 to 2026
$71.4M
Value of End-of-Life Cancer CareI01HX001627 · VA · VETERANS ADMIN PALO ALTO HEALTH CARE SYS · PI MARSZOWSKI, RISHA GIDWANI · 2018 to 2020
–
Improving Analysis of Endogenous Multimodal Treatments for Use in Geriatrics Health Outcomes StudiesI01HX002237 · VA · VA BOSTON HEALTH CARE SYSTEM · PI GARRIDO, MELISSA M · 2018 to 2021
–
HSRD VA 98-004HSRD VA I01 HX001627HSRD VA Merit Review Award Number I01 HX001627HSRD VA SDR 02-237NCI NIH HHS P30 CA124435
6 · The paper itself

Abstract

BACKGROUND/

objectivesTo evaluate differences in end-of-life cost trajectories for cancer patients treated through Medicare versus by the Veterans Health Administration (VA).

designA retrospective analysis of VA and Medicare administrative data from FY 2010 to 2014. We employed three-level generalized estimating equations to evaluate monthly cost trajectories experienced by patients in their last year of life, with patients nested within hospital referral region.

settingCare received at VA facilities or by Medicare-reimbursed providers nationwide.

participantsA total of 36,401 patients dying from cancer and dually enrolled in VA and Medicare. MEASUREMENTS: We evaluated trajectories for total, inpatient, outpatient, and drug costs, using the last 12 months of life. Cost trajectories were prioritized as costs are not directly comparable across Medicare and VA. Patients were assigned to be VA-reliant, Medicare-reliant or Mixed-reliant based on their healthcare utilization in the last year of life.

resultsAll three groups experienced significantly different cost trajectories for total costs in the last year of life. Inpatient cost trajectories were significantly different between Medicare-reliant and VA-reliant patients, but did not differ between VA-reliant and Mixed-reliant patients. Outpatient and drug cost trajectories exhibited the inverse pattern: they were significantly different between VA-reliant and Mixed-reliant patients, but not between VA-reliant and Medicare-reliant patients. However, visual examination of cost trajectories revealed similar cost patterns in the last year of life among all three groups; there was a sharp rise in costs as patients approach death, largely due to inpatient care.

conclusionDespite substantially different financial incentives and organization, VA- and Medicare-treated patients exhibit similar patterns of increasing end-of-life costs, largely driven by inpatient costs. Both systems require improvement to ensure quality of end-of-life care is aligned with recommended practice.

Indexed as

Costs and Cost AnalysisNeoplasmsTerminal CareAgedAmbulatory CareFemaleHospitalizationHospitals, VeteransHumansMaleMedicareNeeds AssessmentPatient Acceptance of Health CareQuality ImprovementUnited StatesUnited States Department of Veterans Affairscancercostsend-of-life careMedicareVeterans Health Administration

Identifiers

PMID33368171
PMCPMC12969846
OpenAlexW3117026192

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.